{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:32:54Z","timestamp":1793946774887,"version":"4.8.0"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Malaysia Ministry of Higher Education","doi-asserted-by":"publisher","award":["FRGS\/1\/2025\/STG01\/USM\/02\/4"],"award-info":[{"award-number":["FRGS\/1\/2025\/STG01\/USM\/02\/4"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jconrel.2026.114894","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:48:39Z","timestamp":1775180919000},"page":"114894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Transdermal delivery and formulation design of opioids: Where are we now and where are we heading?"],"prefix":"10.1016","volume":"394","author":[{"given":"Yi Mo","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juzaili","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng Wooi","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon Fu","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114894_bb0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2125.2012.04317.x","article-title":"Differences between opioids: pharmacological, experimental, clinical and economical perspectives","volume":"75","author":"Drewes","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101198","article-title":"Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study","volume":"42","author":"Jayawardana","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jconrel.2026.114894_bb0015","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/pan.14753","article-title":"Opioid prescription rates associated with surgery among adolescents in the United States from 2015 to 2020","volume":"33","author":"Sofia","year":"2023","journal-title":"Pediatric Anesthesia"},{"key":"10.1016\/j.jconrel.2026.114894_bb0020","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1185\/03007995.2011.569017","article-title":"Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland","volume":"27","author":"Przeklasa-Muszynska","year":"2011","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.jconrel.2026.114894_bb0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jpain.2016.02.015","article-title":"Analysis of the abuse and diversion of the buprenorphine transdermal delivery system","volume":"17","author":"Wiegand","year":"2016","journal-title":"The Journal of Pain"},{"key":"10.1016\/j.jconrel.2026.114894_bb0030","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1007\/s13346-025-01809-9","article-title":"Skin penetration enhancers: mechanistic understanding and their selection for formulation and design","volume":"15","author":"Sim","year":"2025","journal-title":"Drug Delivery and Translational Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0035","series-title":"Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention","article-title":"Chronological information about significant FDA activities related to substance use and overdose prevention","author":"US FDA","year":"2025"},{"key":"10.1016\/j.jconrel.2026.114894_bb0040","series-title":"Drug Approval Package","article-title":"Butrans (buprenorphine) Transdermal System for transdermal administration (5 mcg\/hour, 10 mcg\/hour, and 20 mcg\/hour)","author":"US FDA","year":"2011"},{"key":"10.1016\/j.jconrel.2026.114894_bb0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejpb.2010.02.005","article-title":"Transdermal fentanyl matrix patches Matrifen\u00ae and Durogesic\u00ae DTrans\u00ae are bioequivalent","volume":"75","author":"Kress","year":"2010","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2049463712438493","article-title":"Basic opioid pharmacology: an update","volume":"6","author":"Pathan","year":"2012","journal-title":"British Journal of Pain"},{"key":"10.1016\/j.jconrel.2026.114894_bb0055","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1124\/pr.111.004598","article-title":"Functional selectivity at the \u03bc-opioid receptor: implications for understanding opioid analgesia and tolerance","volume":"63","author":"Raehal","year":"2011","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.jconrel.2026.114894_bb0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/pr.112.005942","article-title":"Regulation of \u03bc-opioid receptors: desensitization, phosphorylation, internalization, and tolerance","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.jconrel.2026.114894_bb0065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jb\/mvae021","article-title":"Morphinan evolution: the impact of advances in biochemistry and molecular biology","volume":"175","author":"Kajino","year":"2024","journal-title":"The Journal of Biochemistry"},{"key":"10.1016\/j.jconrel.2026.114894_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.09.041","article-title":"Molecular recognition of morphine and fentanyl by the human \u03bc-opioid receptor","volume":"185","author":"Zhuang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114894_bb0075","first-page":"23","article-title":"Pharmacology of opioid drugs","author":"Cox","year":"2010","journal-title":"The Opiate Receptors"},{"key":"10.1016\/j.jconrel.2026.114894_bb0080","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1021\/acschemneuro.4c00212","article-title":"Machine learned classification of ligand intrinsic activities at human \u03bc-opioid receptor","volume":"15","author":"Oh","year":"2024","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.jconrel.2026.114894_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197734","article-title":"Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking","volume":"13","author":"Ellis","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2026.114894_bb0090","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00204-020-02684-8","article-title":"Determination of structural factors affecting binding to mu, kappa and delta opioid receptors","volume":"94","author":"Slavov","year":"2020","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0095","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/pharmaceutics11100509","article-title":"Preparation, characterization and dermal delivery of methadone","volume":"11","author":"Kung","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0100","series-title":"Clarke\u2019s analysis of drugs and poisons","author":"Moffat","year":"2011"},{"key":"10.1016\/j.jconrel.2026.114894_bb0105","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.3390\/molecules20034915","article-title":"Understanding the physicochemical properties of mitragynine, a principal alkaloid of Mitragyna speciosa, for preclinical evaluation","volume":"20","author":"Ramanathan","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.114894_bb0110","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.220355","article-title":"Opium alkaloids, biosynthesis, pharmacology and association with cancer occurrence","volume":"13","author":"Vadhel","year":"2023","journal-title":"Open Biology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0115","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/pharmaceutics15061779","article-title":"Synthesis and modification of morphine and codeine, leading to diverse libraries with improved pain relief properties","volume":"15","author":"Zarin","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0120","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00002508-200207001-00002","article-title":"Clinical pharmacology of opioids for pain","volume":"18","author":"Inturrisi","year":"2002","journal-title":"The Clinical Journal of Pain"},{"key":"10.1016\/j.jconrel.2026.114894_bb0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1124\/mol.53.3.377","article-title":"\u03bc-opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism In Vitro and in the mammalian brain","volume":"53","author":"Keith","year":"1998","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neuroscience.2016.06.029","article-title":"Opioid-induced hyperalgesia: cellular and molecular mechanisms","volume":"338","author":"Roeckel","year":"2016","journal-title":"Neuroscience"},{"issue":"14","key":"10.1016\/j.jconrel.2026.114894_bb0135","doi-asserted-by":"crossref","first-page":"E343","DOI":"10.36076\/ppj.2011\/14\/E343","article-title":"Pharmacology of opioids in the treatment of chronic pain syndromes","volume":"4","author":"Vallejo","year":"2011","journal-title":"Pain Physician"},{"key":"10.1016\/j.jconrel.2026.114894_bb0140","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1176\/appi.psy.44.6.515","article-title":"Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II","volume":"44","author":"Armstrong","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0145","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1126\/science.179.4077.1011","article-title":"Opiate receptor: demonstration in nervous tissue","volume":"179","author":"Pert","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.114894_bb0150","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.103.058602","article-title":"Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at \u03bc- and \u03b4-opioid receptors","volume":"308","author":"Thompson","year":"2004","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0155","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/17512433.2018.1537122","article-title":"A spotlight on the role, use, and availability of codeine and the implications faced","volume":"11","author":"Tay","year":"2018","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40262-012-0016-7","article-title":"Pharmacokinetics of non-intravenous formulations of fentanyl","volume":"52","author":"L\u00f6tsch","year":"2013","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0165","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.pbb.2005.11.011","article-title":"Probable activation of the opioid receptor-nitric oxide-cyclic GMP-K+ channels pathway by codeine","volume":"82","author":"Ortiz","year":"2005","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.jconrel.2026.114894_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217371","article-title":"Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids","volume":"14","author":"Olson","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2026.114894_bb0175","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10571-020-01013-y","article-title":"Oxycodone in the opioid epidemic: high 'Liking', 'Wanting', and abuse liability","volume":"41","author":"Kibaly","year":"2021","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0180","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1467-2995.2007.00387.x","article-title":"Comparison of the analgesic efficacy of hydromorphone and oxymorphone in dogs and cats: a randomized blinded study","volume":"35","author":"Bateman","year":"2008","journal-title":"Veterinary Anaesthesia and Analgesia"},{"key":"10.1016\/j.jconrel.2026.114894_bb0185","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/pm\/pnx050","article-title":"Hydrocodone is more effective than morphine or oxycodone in suppressing the development of burn-induced mechanical allodynia","volume":"18","author":"Emery","year":"2017","journal-title":"Pain Medicine"},{"key":"10.1016\/j.jconrel.2026.114894_bb0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/bja\/aer115","article-title":"Opioid receptor subtypes: fact or artifact?","volume":"107","author":"Dietis","year":"2011","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.jconrel.2026.114894_bb0195","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/mol.119.119214","article-title":"Intrinsic efficacy of opioid ligands and its importance for apparent bias, operational analysis, and therapeutic window","volume":"98","author":"Gillis","year":"2020","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0200","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/acs.jcim.0c00890","article-title":"Structural assessment of agonist efficacy in the \u03bc-opioid receptor: morphine and fentanyl elicit different activation patterns","volume":"61","author":"Ricarte","year":"2021","journal-title":"Journal of Chemical Information and Modeling"},{"key":"10.1016\/j.jconrel.2026.114894_bb0205","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/383819a0","article-title":"Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the \u03bc-opioid-receptor gene","volume":"383","author":"Matthes","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.114894_bb0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","article-title":"A review: Fentanyl and non-pharmaceutical fentanyls","volume":"171","author":"Suzuki","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jconrel.2026.114894_bb0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.24875\/RIC.23000109","article-title":"Fentanyl and other new psychoactive synthetic opioids","volume":"75","author":"Albores-Garc\u00eda","year":"2023","journal-title":"Challenges to Prevention and Treatment, Revista de investigaci\u00f3n cl\u00ednica"},{"key":"10.1016\/j.jconrel.2026.114894_bb0220","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-pharmtox-052120-091058","article-title":"Biased agonism: lessons from studies of opioid receptor agonists","volume":"63","author":"Kelly","year":"2023","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0225","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1021\/acschemneuro.8b00174","article-title":"DARK classics in chemical neuroscience: fentanyl","volume":"9","author":"Burns","year":"2018","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.jconrel.2026.114894_bb0230","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3389\/fphar.2018.01145","article-title":"Drug interactions with new synthetic opioids","volume":"9","author":"P\u00e9rez-Ma\u00f1\u00e1","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00561676","article-title":"Clinical pharmacokinetics and oral bioavailability of ketobemidone","volume":"17","author":"Bondesson","year":"1980","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0240","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1399-6576.2009.02135.x","article-title":"Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children","volume":"54","author":"Lundeberg","year":"2010","journal-title":"Acta Anaesthesiologica Scandinavica"},{"key":"10.1016\/j.jconrel.2026.114894_bb0245","article-title":"Chronopharmacodynamics and chronopharmacokinetics of pethidine in mice","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2026.114894_bb0250","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bja.2019.08.010","article-title":"The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review","volume":"124","author":"Baldo","year":"2020","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.jconrel.2026.114894_bb0255","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/archsurg.137.1.84","article-title":"Use of meperidine in patient-controlled analgesia and the development of a normeperidine toxic reaction","volume":"137","author":"Simopoulos","year":"2002","journal-title":"Archives of Surgery"},{"key":"10.1016\/j.jconrel.2026.114894_bb0260","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1399-6576.2004.00524.x","article-title":"Comparison of the analgesic efficacy of ketobemidone and morphine for management of postoperative pain in children: a randomized, controlled study","volume":"48","author":"Jylli","year":"2004","journal-title":"Acta Anaesthesiologica Scandinavica"},{"key":"10.1016\/j.jconrel.2026.114894_bb0265","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0304-3959(96)03123-5","article-title":"The opioid ketobemidone has a NMDA blocking effect","volume":"67","author":"Andersen","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.jconrel.2026.114894_bb0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1056-8719(00)00043-5","article-title":"Methadone: a review of its pharmacokinetic\/pharmacodynamic properties","volume":"42","author":"Garrido","year":"1999","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.jconrel.2026.114894_bb0275","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/ph18050623","article-title":"The relevance of pharmacokinetic biomarkers in response to methadone treatment: a systematic review","volume":"18","author":"Recarey-Rama","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2026.114894_bb0280","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/01.ftd.0000211827.03726.e4","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain","volume":"28","author":"Auret","year":"2006","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.jconrel.2026.114894_bb0285","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-024-02128-y","article-title":"Buprenorphine pharmacodynamics: a bridge to understanding buprenorphine clinical benefits","volume":"85","author":"Davis","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2026.114894_bb0290","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.4103\/IJPC.IJPC_180_17","article-title":"Practical pharmacology of methadone: a long-acting opioid","volume":"24","author":"Sunilkumar","year":"2018","journal-title":"Indian Journal of Palliative Care"},{"key":"10.1016\/j.jconrel.2026.114894_bb0295","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/cc5150","article-title":"Case report: quantification of methadone-induced respiratory depression using toxicokinetic\/toxicodynamic relationships","volume":"11","author":"M\u00e9garbane","year":"2007","journal-title":"Critical Care"},{"key":"10.1016\/j.jconrel.2026.114894_bb0300","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40122-019-00143-6","article-title":"A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain","volume":"9","author":"Gudin","year":"2020","journal-title":"Pain and Therapy"},{"key":"10.1016\/j.jconrel.2026.114894_bb0305","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1570159043359477","article-title":"Buprenorphine: a unique drug with complex pharmacology","volume":"2","author":"Lutfy","year":"2004","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0310","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bja.2021.12.001","article-title":"Buprenorphine: a treatment and cause of opioid-induced respiratory depression","volume":"128","author":"Dahan","year":"2022","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.jconrel.2026.114894_bb0315","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/biom11060816","article-title":"Buprenorphine: far beyond the \u201cCeiling\u201d","volume":"11","author":"Infantino","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2026.114894_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256752","article-title":"Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: a placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients","volume":"17","author":"Moss","year":"2022","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2026.114894_bb0325","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/medicina60020195","article-title":"Optimal post-operative nalbuphine dose regimen: a randomized controlled trial in patients with laparoscopic cholecystectomy","volume":"60","author":"Chen","year":"2024","journal-title":"Medicina"},{"key":"10.1016\/j.jconrel.2026.114894_bb0330","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1254\/jphs.CRJ05001X","article-title":"Butorphanol: effects of a prototypical agonist-antagonist analgesic on \u03ba-opioid receptors","volume":"98","author":"Commiskey","year":"2005","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-015-0043-3","article-title":"Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus","volume":"16","author":"Hawi","year":"2015","journal-title":"BMC Nephrology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0340","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.2147\/DDDT.S371596","article-title":"Pharmacokinetic study of nalbuphine in surgical patients undergoing general anesthesia with varying degrees of liver dysfunction","volume":"16","author":"Gao","year":"2022","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.jconrel.2026.114894_bb0345","first-page":"252","article-title":"Zastosowanie nalbufiny w anestezjologii pediatrycznej, Anestezjologia Intensywna","volume":"47","author":"Kubica-Cieli\u0144ska","year":"2015","journal-title":"Terapia"},{"key":"10.1016\/j.jconrel.2026.114894_bb0350","doi-asserted-by":"crossref","first-page":"837492","DOI":"10.3389\/fped.2022.837492","article-title":"Pharmacometric analysis of intranasal and intravenous nalbuphine to optimize pain management in infants","volume":"10","author":"Pfiffner","year":"2022","journal-title":"Frontiers in Pediatrics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0355","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejps.2014.05.003","article-title":"Sulfation of opioid drugs by human cytosolic sulfotransferases: Metabolic labeling study and enzymatic analysis","volume":"62","author":"Kurogi","year":"2014","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0360","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/(SICI)1099-081X(199704)18:3<191::AID-BDD9>3.0.CO;2-6","article-title":"The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans","volume":"18","author":"Vachharajani","year":"1997","journal-title":"Biopharmaceutics & Drug Disposition"},{"key":"10.1016\/j.jconrel.2026.114894_bb0365","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0090-9556(25)00262-4","article-title":"Disposition of parenteral butorphanol in man","volume":"8","author":"Gaver","year":"1980","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.jconrel.2026.114894_bb0370","doi-asserted-by":"crossref","first-page":"10927","DOI":"10.1038\/srep10927","article-title":"A comparision of nalbuphine with morphine for analgesic effects and safety : meta-analysis of randomized controlled trials","volume":"5","author":"Zeng","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.jconrel.2026.114894_bb0375","doi-asserted-by":"crossref","first-page":"289","DOI":"10.59958\/hsf.7221","article-title":"Safety and efficacy of butorphanol as an analgesic for patients on mechanical ventilation after cardiac surgery: an exploratory prospective observational study","volume":"27","author":"Huang","year":"2024","journal-title":"Heart Surgery Forum"},{"key":"10.1016\/j.jconrel.2026.114894_bb0380","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.3390\/cancers14153617","article-title":"Comparison of side effects of nalbuphine and morphine in the treatment of pain in children with cancer: a prospective study","author":"Kubica-Cieli\u0144ska","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.114894_bb0385","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1111\/bcp.15663","article-title":"A population pharmacokinetic\u2013pharmacodynamic model evaluating efficacy of nalbuphine extended-release in patients with prurigo nodularis","volume":"89","author":"Eudy-Byrne","year":"2023","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050169","article-title":"Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological fMRI","volume":"8","author":"Gear","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2026.114894_bb0395","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0091-3057(84)90300-9","article-title":"Agonist-antagonistic interactions of pentazocine with morphine studied in mice","volume":"20","author":"Shimada","year":"1984","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.jconrel.2026.114894_bb0400","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3390\/pharmaceutics14020409","article-title":"Physicochemical characterizations and pharmacokinetic evaluation of pentazocine solid lipid nanoparticles against inflammatory pain model","volume":"14","author":"Khan","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0405","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1248\/bpb.b22-00398","article-title":"Pharmacokinetic\/pharmacodynamic modeling and simulation of the analgesic effects of pentazocine using perioperative real-world data","volume":"45","author":"Omori","year":"2022","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.jconrel.2026.114894_bb0410","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003495-197305010-00002","article-title":"Pentazocine: a review of its pharmacological properties, therapeutic efficacy and dependence liability","volume":"5","author":"Brogden","year":"1973","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2026.114894_bb0415","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/BF03039145","article-title":"Pharmacokinetic-pharmacodynamic modeling of pentazocine under general anesthesia \u2014Effect of infusion period on respiratory rate\u2014","volume":"86","author":"Tanaka","year":"1998","journal-title":"Shigaku = Odontology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0420","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215337","article-title":"Pentazocine abuse in a healthcare professional","volume":"2016","author":"Dar\u00e7\u0131n","year":"2016","journal-title":"BMJ Case Reports"},{"key":"10.1016\/j.jconrel.2026.114894_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-197305010-00001","article-title":"The clinical pharmacology of pentazocine","volume":"5","author":"Payne","year":"1973","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2026.114894_bb0430","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/ph18020222","article-title":"Exploring the therapeutic potential of mitragynine and corynoxeine: kratom-derived indole and oxindole alkaloids for pain management","volume":"18","author":"Alford","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2026.114894_bb0435","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1021\/acscentsci.9b00141","article-title":"7-hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects","volume":"5","author":"Kruegel","year":"2019","journal-title":"ACS Central Science"},{"key":"10.1016\/j.jconrel.2026.114894_bb0440","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76119-w","article-title":"Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions","volume":"10","author":"Todd","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.jconrel.2026.114894_bb0445","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.biopha.2015.01.022","article-title":"Tramadol hydrochloride: Pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems","volume":"70","author":"Vazzana","year":"2015","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.jconrel.2026.114894_bb0450","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11419-020-00569-0","article-title":"A review on tramadol toxicity: mechanism of action, clinical presentation, and treatment","volume":"39","author":"Nakhaee","year":"2021","journal-title":"Forensic Toxicology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0455","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3390\/ph18070971","article-title":"Pharmacogenomics and pharmacometabolomics in precision tramadol prescribing for enhanced pain management: evidence from QBB and EMR data","author":"Dhieb","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2026.114894_bb0460","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejp.1196","article-title":"Comparative pharmacology and toxicology of tramadol and tapentadol","volume":"22","author":"Faria","year":"2018","journal-title":"European Journal of Pain"},{"key":"10.1016\/j.jconrel.2026.114894_bb0465","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/2049463716657363","article-title":"Is tapentadol different from classical opioids? A review of the evidence","volume":"10","author":"Langford","year":"2016","journal-title":"British Journal of Pain"},{"key":"10.1016\/j.jconrel.2026.114894_bb0470","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1124\/jpet.110.175042","article-title":"Synergistic interaction between the two mechanisms of action of tapentadol in analgesia","volume":"337","author":"Schr\u00f6der","year":"2011","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0475","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1023\/A:1015944018555","article-title":"Transdermal delivery of narcotic analgesics: comparative permeabilities of narcotic analgesics through human cadaver skin","volume":"6","author":"Roy","year":"1989","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0480","series-title":"British National Formulary [Internet]","article-title":"Joint Formulary Committee, Codeine phosphate","year":"2025"},{"key":"10.1016\/j.jconrel.2026.114894_bb0485","series-title":"British National Formulary [Internet]","article-title":"Joint Formulary Committee, Tramadol hydrochloride","year":"2025"},{"key":"10.1016\/j.jconrel.2026.114894_bb0490","series-title":"Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement: Drug Manipulation Strategies and Vehicle Effects","first-page":"3","article-title":"Skin deep: the basics of human skin structure and drug penetration","author":"Ng","year":"2015"},{"key":"10.1016\/j.jconrel.2026.114894_bb0495","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jconrel.2026.114894_bb0500","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.burns.2009.05.013","article-title":"Human body surface area database and estimation formula","volume":"36","author":"Yu","year":"2010","journal-title":"Burns"},{"key":"10.1016\/j.jconrel.2026.114894_bb0505","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone","volume":"41","author":"Eap","year":"2002","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0510","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3109\/03639045.2015.1071832","article-title":"Formulation optimisation of a drug in adhesive transdermal analgesic patch","volume":"42","author":"Ravula","year":"2016","journal-title":"Drug Dev Ind Pharm"},{"issue":"1-2","key":"10.1016\/j.jconrel.2026.114894_bb0515","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2013.02.040","article-title":"Skin penetration enhancers","volume":"447","author":"Lane","year":"2013","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0520","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1007\/s13346-025-01809-9","article-title":"Skin penetration enhancers: mechanistic understanding and their selection for formulation and design","volume":"15","author":"Sim","year":"2025","journal-title":"Drug Delivery and Translational Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0525","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.bbamem.2009.08.015","article-title":"Enhancement of transdermal drug delivery via synergistic action of chemicals","volume":"1788","author":"Karande","year":"2009","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes"},{"key":"10.1016\/j.jconrel.2026.114894_bb0530","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0378-5173(93)90415-C","article-title":"A new enhancer-coenhancer system to increase skin permeation of morphine hydrochloride in vitro","volume":"91","author":"Morimoto","year":"1993","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0535","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1248\/bpb.16.600","article-title":"Influence of composition of l-menthol-ethanol-water ternary solvent system on the transdermal delivery of morphine hydrochloride","volume":"16","author":"Wada","year":"1993","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"10.1016\/j.jconrel.2026.114894_bb0540","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1248\/bpb.25.134","article-title":"In vitro skin permeation of morphine hydrochloride during the finite application of penetration-enhancing system containing water, ethanol and l-menthol","volume":"25","author":"Morimoto","year":"2002","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"10.1016\/j.jconrel.2026.114894_bb0545","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/bdd.2510150805","article-title":"The effect of different routes of administration on the metabolism of morphine: the disposition of morphine and its metabolites after topical application","volume":"15","author":"Matsuzawa","year":"1994","journal-title":"Biopharmaceutics and Drug Disposition"},{"key":"10.1016\/j.jconrel.2026.114894_bb0550","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0378-5173(01)00830-4","article-title":"Comparison of the effect of ultrasound and of chemical enhancers on transdermal permeation of caffeine and morphine through hairless mouse skin in vitro","volume":"229","author":"Monti","year":"2001","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0555","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/00498258709043943","article-title":"Transdermal drug delivery and cutaneous metabolism","volume":"17","author":"Guy","year":"1987","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114894_bb0560","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.3390\/molecules20034915","article-title":"Understanding the physicochemical properties of mitragynine, a principal alkaloid of Mitragyna speciosa, for preclinical evaluation","volume":"20","author":"S","year":"2015","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114894_bb0565","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","article-title":"Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges","volume":"17","author":"H","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.jconrel.2026.114894_bb0570","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1211\/jpp.59.7.0002","article-title":"Ester prodrugs of morphine improve transdermal drug delivery: a mechanistic study","volume":"59","author":"Wang","year":"2007","journal-title":"Journal of Pharmacy and Pharmacology"},{"issue":"12","key":"10.1016\/j.jconrel.2026.114894_bb0575","doi-asserted-by":"crossref","first-page":"20780","DOI":"10.3390\/molecules191220780","article-title":"Prodrug strategies for enhancing the percutaneous absorption of drugs","volume":"19","author":"DD","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.114894_bb0580","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0378-5173(91)90072-V","article-title":"Utilisation of prodrugs to enhance the transdermal absorption of morphine","volume":"71","author":"Drustrup","year":"1991","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0585","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/sct.1989.5.119","article-title":"Utility of topical formulations of morphine hydrochloride containing azone and N-methyl-2-pyrrolidone","volume":"5","author":"Sugibayashi","year":"1989","journal-title":"Selective Cancer Therapeutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0590","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1525-1594.1994.tb02233.x","article-title":"Electromotive administration of a new morphine formulation: morphine citrate","volume":"18","author":"Stephen","year":"1994","journal-title":"Artificial Organs"},{"key":"10.1016\/j.jconrel.2026.114894_bb0595","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0190-9622(88)70247-9","article-title":"Painless cauterization of spider veins with the use of iontophoretic local anesthesia","volume":"19","author":"Bezzant","year":"1988","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0600","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10103-007-0452-z","article-title":"Skin pretreatment with an Er:YAG laser promotes the transdermal delivery of three narcotic analgesics","volume":"22","author":"Lee","year":"2007","journal-title":"Lasers in Medical Science"},{"key":"10.1016\/j.jconrel.2026.114894_bb0605","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0168-3659(90)90126-E","article-title":"In vitro and in vivo evaluation of transdermal iontophoretic delivery of hydromorphone","volume":"11","author":"Padmanabhan","year":"1990","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jconrel.2026.114894_bb0610","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/10837450802409479","article-title":"Transdermal iontophoresis of hydromorphone across hairless rat skin in vitro","volume":"14","author":"Kumar","year":"2009","journal-title":"Pharmaceutical Development and Technology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0615","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/jps.2600791207","article-title":"Transdermal oxymorphone formulation development and methods for evaluating flux and lag times for two skin permeation-enhancing vehicles","volume":"79","author":"Blake","year":"1990","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0620","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3109\/03639048909043672","article-title":"In-vitro transdermal permeation of oxycodone: (I) effect of PH, delipidization and skin stripping","volume":"15","author":"Kuo","year":"1989","journal-title":"Drug Development and Industrial Pharmacy"},{"key":"10.1016\/j.jconrel.2026.114894_bb0625","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/jps.2600800806","article-title":"Transdermal-controlled administration of oxycodone","volume":"80","author":"Tien","year":"1991","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0630","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/jps.24502","article-title":"Topical application of a novel oxycodone gel formulation (tocopheryl phosphate mixture) in a rat model of peripheral inflammatory pain produces localized pain relief without significant systemic exposure","volume":"104","author":"Smith","year":"2015","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0635","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijpharm.2011.01.025","article-title":"Enhanced permeation of fentanyl from supersaturated solutions in a model membrane","volume":"407","author":"Santos","year":"2011","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0640","first-page":"155","article-title":"Formulation issues associated with transdermal fentanyl delivery","volume":"416","author":"Santos","year":"2011","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0645","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijpharm.2012.09.031","article-title":"Influence of penetration enhancer on drug permeation from volatile formulations","volume":"439","author":"Santos","year":"2012","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0650","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/js950415w","article-title":"Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design","volume":"85","author":"Roy","year":"1996","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0655","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0168-3659(00)00268-6","article-title":"Evaluation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) gels as a release vehicle for percutaneous fentanyl","volume":"68","author":"Liaw","year":"2000","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jconrel.2026.114894_bb0660","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1208\/s12249-009-9366-3","article-title":"Preparation and in vitro evaluation of a new fentanyl patch based on functional and non-functional pressure sensitive adhesives","volume":"11","author":"Taghizadeh","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2026.114894_bb0665","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1023\/A:1016093920875","article-title":"Transdermal delivery of fentanyl by electroporation. I. Influence of electrical factors","volume":"13","author":"Vanbever","year":"1996","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0670","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1023\/A:1016073917125","article-title":"Transdermal delivery of fentanyl by electroporation. II. Mechanisms involved in drug transport","volume":"13","author":"Vanbever","year":"1996","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0675","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1023\/A:1015135426838","article-title":"Electrically modulated transdermal delivery of fentanyl","volume":"19","author":"Conjeevaram","year":"2002","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0680","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jps.22765","article-title":"Transdermal delivery using a novel electrochemical device, part 1: device design and in vitro release\/permeation of fentanyl","volume":"101","author":"Schr\u00f6der","year":"2012","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0685","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/jps.23108","article-title":"Transdermal delivery using a novel electrochemical device, part 2: In Vivo study in humans","volume":"101","author":"Schr\u00f6der","year":"2012","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0690","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0378-5173(01)00820-1","article-title":"In vitro study of low-frequency ultrasound-enhanced transdermal transport of fentanyl and caffeine across human and hairless rat skin","volume":"228","author":"Boucaud","year":"2001","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0695","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0378-5173(92)90163-V","article-title":"Enhanced transdermal delivery of ketobemidone with prodrugs","volume":"84","author":"Hansen","year":"1992","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0700","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejphar.2007.10.014","article-title":"Analgesic synergy between topical opioids and topical non-steroidal anti-inflammatory drugs in the mouse model of thermal pain","volume":"579","author":"Kolesnikov","year":"2008","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11100509","article-title":"Preparation, characterization and dermal delivery of methadone","volume":"11","author":"Kung","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119538","article-title":"Investigation of binary and ternary solvent systems for dermal delivery of methadone","volume":"586","author":"Kung","year":"2020","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0715","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/10837459609022597","article-title":"Development of a transdermal patch of methadone: in vitro evaluation across hairless mouse and human cadaver skin","volume":"1","author":"Ghosh","year":"1996","journal-title":"Pharmaceutical Development and Technology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0720","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jddst.2017.04.011","article-title":"Design, development and characterization of transdermal patch of methadone","volume":"42","author":"Mu\u00f1oz","year":"2017","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0725","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jps.2600830204","article-title":"Transdermal delivery of buprenorphine through cadaver skin","volume":"83","author":"Roy","year":"1994","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0730","first-page":"4","article-title":"In vitro skin permeation of buprenorphine transdermal patch","volume":"16","author":"Liao","year":"2008","journal-title":"Journal of Food and Drug Analysis"},{"key":"10.1016\/j.jconrel.2026.114894_bb0735","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jare.2014.01.006","article-title":"A statistical experimental design approach to evaluate the influence of various penetration enhancers on transdermal drug delivery of buprenorphine","volume":"6","author":"Taghizadeh","year":"2015","journal-title":"Journal of Advanced Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0740","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1248\/bpb.19.263","article-title":"Transdermal prodrug concepts: permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles","volume":"19","author":"Imoto","year":"1996","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"10.1016\/j.jconrel.2026.114894_bb0745","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1023\/A:1016079513007","article-title":"Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin","volume":"13","author":"Stinchcomb","year":"1996","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0750","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3109\/02652040902746679","article-title":"Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: lipid emulsion, nanostructured lipid carriers and solid lipid nanoparticles","volume":"26","author":"Wang","year":"2009","journal-title":"Journal of Microencapsulation"},{"key":"10.1016\/j.jconrel.2026.114894_bb0755","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0168-3659(01)00298-X","article-title":"Electrically-assisted transdermal delivery of buprenorphine","volume":"73","author":"Bose","year":"2001","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jconrel.2026.114894_bb0760","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1211\/002235702760345392","article-title":"The effects of iontophoresis and electroporation on transdermal delivery of buprenorphine from solutions and hydrogels","volume":"54","author":"Fang","year":"2002","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(99)00269-2","article-title":"Delivery of nalbuphine and its prodrugs across skin by passive diffusion and iontophoresis","volume":"67","author":"Sung","year":"2000","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jconrel.2026.114894_bb0770","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0928-0987(02)00244-0","article-title":"Transdermal delivery of nalbuphine and its prodrugs by electroporation","volume":"18","author":"Sung","year":"2003","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0775","first-page":"408","article-title":"Transdermal delivery of nalbuphine and nalbuphine pivalate from hydrogels by passive diffusion and iontophoresis","volume":"51","author":"Fang","year":"2001","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jconrel.2026.114894_bb0780","first-page":"162","article-title":"The effects of electrically assisted methods on transdermal delivery of nalbuphine bensoate and sebacoyl dinalbuphine ester from solutions and hydrogels","volume":"297","author":"Huang","year":"2005","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0785","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0168-3659(01)00391-1","article-title":"Transdermal drug delivery enhanced and controlled by erbium:YAG laser: a comparative study of lipophilic and hydrophilic drugs","volume":"75","author":"Lee","year":"2001","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jconrel.2026.114894_bb0790","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/03639040601128639","article-title":"In vitro studies on transdermal permeation of butorphanol","volume":"33","author":"Svozil","year":"2007","journal-title":"Drug Development and Industrial Pharmacy"},{"key":"10.1016\/j.jconrel.2026.114894_bb0795","first-page":"130","article-title":"Reservoir type transdermal delivery systems of pentazocine hydrochloride","volume":"1","author":"Saini","year":"2008","journal-title":"Rasayan Journal of Chemistry"},{"key":"10.1016\/j.jconrel.2026.114894_bb0800","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1248\/bpb.31.1439","article-title":"Formulation and in vitro evaluation of pentazocine transdermal delivery system","volume":"31","author":"Furuishi","year":"2008","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"10.1016\/j.jconrel.2026.114894_bb0805","series-title":"Pharmacology and Therapeutics","first-page":"883","article-title":"Chapter 61 - Treatment of Pain","author":"Gandhi","year":"2009"},{"key":"10.1016\/j.jconrel.2026.114894_bb0810","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2478\/v10007-009-0014-y","article-title":"Development of matrix controlled transdermal delivery systems of pentazocine: performance","volume":"59","author":"Prasad Verma","year":"2009","journal-title":"Acta Pharmaceutica"},{"key":"10.1016\/j.jconrel.2026.114894_bb0815","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1208\/s12249-018-0967-6","article-title":"Enhancement of dissolution and skin permeability of pentazocine by proniosomes and niosomal gel","volume":"19","author":"Madni","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2026.114894_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123316","article-title":"Development and validation of a gradient HPLC-UV method for mitragynine following in vitro skin permeation studies","volume":"1204","author":"Sim","year":"2022","journal-title":"Journal of Chromatography B"},{"key":"10.1016\/j.jconrel.2026.114894_bb0825","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1007\/s13346-025-01933-6","article-title":"In vitro skin permeation of mitragynine: Optimisation of antioxidants for enhanced drug stability and formulation performance","volume":"15","author":"Sim","year":"2025","journal-title":"Drug Delivery and Translational Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.indcrop.2023.117909","article-title":"Mitragyna speciosa ethanolic extract: extraction, anti-inflammatory, cytotoxicity, and transdermal delivery assessments","volume":"208","author":"Tuntiyasawasdikul","year":"2024","journal-title":"Industrial Crops and Products"},{"key":"10.1016\/j.jconrel.2026.114894_bb0835","first-page":"451","article-title":"Preparation and evaluation of 5, 9-dimethyl-2-cyclopropyl-2-decanol as a penetration enhancer for drugs through rat skin","volume":"24","author":"Khan","year":"2011","journal-title":"Pakistan Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0840","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.xphs.2022.05.013","article-title":"Preparation and evaluation of hydrogel film containing tramadol for reduction of peripheral neuropathic pain","volume":"112","author":"Natori","year":"2023","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0845","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1208\/s12249-008-9167-0","article-title":"Polymeric matrix system for prolonged delivery of tramadol hydrochloride, part I: physicochemical evaluation","volume":"10","author":"Ammar","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2026.114894_bb0850","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1208\/s12249-009-9294-2","article-title":"Polymeric matrix system for prolonged delivery of tramadol hydrochloride, part ii: biological evaluation","volume":"10","author":"Ammar","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2026.114894_bb0855","first-page":"1475","article-title":"The role of surfactants in the formulation of elastic liposomal gels containing a synthetic opioid analgesic","volume":"11","author":"Singh","year":"2016","journal-title":"International Journal of Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114894_bb0860","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.2042-7158.2011.01355.x","article-title":"In-vitro and in-vivo transdermal iontophoretic delivery of tramadol, a centrally acting analgesic","volume":"63","author":"Takasuga","year":"2011","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0865","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5530\/ijper.51.4.81","article-title":"Formulation and characterization of tapentadol loaded emulgel for topical application","volume":"51","author":"Ambhore","year":"2017","journal-title":"Indian Journal of Pharmaceutical Education and Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122274","article-title":"Employment of PEGylated ultra-deformable transferosomes for transdermal delivery of tapentadol with boosted bioavailability and analgesic activity in post-surgical pain","volume":"628","author":"Deng","year":"2022","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0875","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/bph.13059","article-title":"Transdermal patches: history, development and pharmacology","volume":"172","author":"Pastore","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0880","series-title":"Topical and Transdermal Drug Delivery \u2013 Principles and Practice","first-page":"357","article-title":"Transdermal and topical drug delivery today","author":"Watkinson","year":"2012"},{"key":"10.1016\/j.jconrel.2026.114894_bb0885","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1023\/A:1015912932416","article-title":"Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil","volume":"7","author":"Roy","year":"1990","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb0890","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/jps.2600831215","article-title":"Transdermal delivery of narcotic analgesics: comparative metabolism and permeability of human cadaver skin and hairless mouse skin","volume":"83","author":"Roy","year":"1994","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0895","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a058765","article-title":"Oral tramadol, a \u03bc-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain","volume":"5","author":"Wilder-Smith","year":"1994","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0900","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cden.2011.09.001","article-title":"Management of acute postoperative pain after oral surgery","volume":"56","author":"Fletcher","year":"2012","journal-title":"Dental Clinics of North America"},{"key":"10.1016\/j.jconrel.2026.114894_bb0905","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bja\/42.2.169","article-title":"An assessment of the analgesic efficacy of oral pentazocine","volume":"42","author":"Davie","year":"1970","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.jconrel.2026.114894_bb0910","series-title":"Pain Management (Second Edition)","first-page":"890","article-title":"Chapter 122 - opioid analgesics","author":"Koyyalagunta","year":"2011"},{"key":"10.1016\/j.jconrel.2026.114894_bb0915","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/papr.12238","article-title":"Sufentanil sublingual tablet system vs. intravenous patient-controlled analgesia with morphine for postoperative pain control: a randomized, active-comparator trial","volume":"14","author":"Melson","year":"2014","journal-title":"Pain Practice"},{"key":"10.1016\/j.jconrel.2026.114894_bb0920","series-title":"WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents","author":"WHO","year":"2018"},{"key":"10.1016\/j.jconrel.2026.114894_bb0925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2014 United States","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep 2022"},{"key":"10.1016\/j.jconrel.2026.114894_bb0930","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jpainsymman.2009.06.004","article-title":"Opioid equianalgesic tables: are they all equally dangerous?","volume":"38","author":"Shaheen","year":"2009","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1016\/j.jconrel.2026.114894_bb0935","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/10667857.2020.1802839","article-title":"Tailoring hybrid organic-inorganic film forming topical gel: A tuneable approach for Tramadol HCl delivery","volume":"36","author":"Kendre","year":"2021","journal-title":"Materials Technology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0940","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1248\/cpb.46.882","article-title":"Effect of several hydrophilic polymers on the permeation of morphine and salicylic acid through excised hairless rat skin","volume":"46","author":"Hosoya","year":"1998","journal-title":"Chemical and Pharmaceutical Bulletin"},{"key":"10.1016\/j.jconrel.2026.114894_bb0945","first-page":"636","article-title":"In-vitro; ex-vivo assessment of anti-inflammatory Tapentadol loaded non-ionic surfactant vesicular systems for effective transdermal delivery","volume":"11","author":"Jabbar","year":"2020","journal-title":"Systematic Reviews in Pharmacy"},{"key":"10.1016\/j.jconrel.2026.114894_bb0950","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2340\/00015555-0480","article-title":"In vitro and In vivo characterization of a novel liposomal butorphanol formulation for treatment of pruritus","volume":"88","author":"Lim","year":"2008","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.jconrel.2026.114894_bb0955","doi-asserted-by":"crossref","DOI":"10.4274\/tjps.galenos.2021.43678","article-title":"Fabrication and evaluation of matrix type novel transdermal patch loaded with tramadol hydrochloride","volume":"19","author":"Nandi","year":"2022","journal-title":"Turkish Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jconrel.2026.114894_bb0960","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2125.1994.tb04306.x","article-title":"Transdermal administration of morphine to healthy subjects","volume":"37","author":"Westerling","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0965","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jpainsymman.2011.10.022","article-title":"Novel patch for transdermal administration of morphine","volume":"44","author":"Inui","year":"2012","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1016\/j.jconrel.2026.114894_bb0970","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2217\/pmt-2016-0068","article-title":"Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture\/oxycodone transdermal patch system: a phase i study","volume":"7","author":"Gavin","year":"2017","journal-title":"Pain Management"},{"key":"10.1016\/j.jconrel.2026.114894_bb0975","series-title":"Itch: Mechanisms and Treatment","article-title":"Peripheral opioids","author":"Bigliardi","year":"2014"},{"key":"10.1016\/j.jconrel.2026.114894_bb0980","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/exd.13021","article-title":"Opioids and skin homeostasis, regeneration and ageing \u2013 What's the evidence?","volume":"25","author":"Bigliardi","year":"2016","journal-title":"Experimental Dermatology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0985","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1600-0625.2009.00844.x","article-title":"Opioids and the skin \u2013 where do we stand?","volume":"18","author":"Bigliardi","year":"2009","journal-title":"Experimental Dermatology"},{"key":"10.1016\/j.jconrel.2026.114894_bb0990","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2015.04.071","article-title":"On the selection of an opioid for local skin analgesia: structure-skin permeability relationships","volume":"489","author":"Musazzi","year":"2015","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb0995","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/bja\/ael314","article-title":"Fentanyl HCl iontophoretic transdermal system (ITS): clinical application of iontophoretic technology in the management of acute postoperative pain","volume":"98","author":"Power","year":"2007","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.jconrel.2026.114894_bb1000","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40122-016-0061-2","article-title":"Use of Fentanyl Iontophoretic Transdermal System (ITS) (IONSYS\u00ae) in the management of patients with acute postoperative pain: a case series","volume":"5","author":"Poplawski","year":"2016","journal-title":"Pain and Therapy"},{"key":"10.1016\/j.jconrel.2026.114894_bb1005","series-title":"Ionsys","author":"EMA","year":"2008"},{"key":"10.1016\/j.jconrel.2026.114894_bb1010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2024.11.056","article-title":"White paper: Understanding, informing and defining the regulatory science of microneedle-based dosage forms that are applied to the skin","volume":"378","author":"Dul","year":"2025","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jconrel.2026.114894_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113794","article-title":"Dissolving microneedles in transdermal drug delivery: A critical analysis of limitations and translation challenges","volume":"383","author":"Moawad","year":"2025","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jconrel.2026.114894_bb1020","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1007\/s13346-025-01888-8","article-title":"Assessing the integrity and mechanical properties of commercial microneedles: innovation or fad?","volume":"15","author":"Lee","year":"2025","journal-title":"Drug Delivery and Translational Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb1025","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12111113","article-title":"The current status of clinical research involving microneedles: a systematic review","volume":"12","author":"Jeong","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb1030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11095-023-03621-x","article-title":"Fabrication and characterization of dissolving microneedles for transdermal drug delivery of apomorphine hydrochloride in Parkinson\u2019s Disease","volume":"41","author":"Ando","year":"2024","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.jconrel.2026.114894_bb1035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13181-012-0263-x","article-title":"Likeability and abuse liability of commonly prescribed opioids","volume":"8","author":"Wightman","year":"2012","journal-title":"Journal of Medical Toxicology"},{"key":"10.1016\/j.jconrel.2026.114894_bb1040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/toxics11010046","article-title":"Atypical fentanyl transdermal patch consumption and fatalities: case report and literature review","volume":"11","author":"Manetti","year":"2023","journal-title":"Toxics"},{"key":"10.1016\/j.jconrel.2026.114894_bb1045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00325481.2017.1269596","article-title":"Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System","volume":"129","author":"Coplan","year":"2017","journal-title":"Postgraduate Medicine"},{"key":"10.1016\/j.jconrel.2026.114894_bb1050","article-title":"Fentanyl transdermal patch: the silent new killer?","volume":"2","author":"Zanon","year":"2020","journal-title":"Forensic Science International: Reports"},{"key":"10.1016\/j.jconrel.2026.114894_bb1055","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jemermed.2011.05.017","article-title":"Whole fentanyl patch ingestion: a multi-center case series","volume":"42","author":"Mrvos","year":"2012","journal-title":"Journal of Emergency Medicine"},{"key":"10.1016\/j.jconrel.2026.114894_bb1060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1517\/13543780902751622","article-title":"Opioid formulations in development designed to curtail abuse: who is the target?","volume":"18","author":"Webster","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.jconrel.2026.114894_bb1065","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/17512433.2018.1545573","article-title":"Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain","volume":"11","author":"Fanelli","year":"2018","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.jconrel.2026.114894_bb1070","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/00325481.2017.1268902","article-title":"Current and future development of extended-release, abuse-deterrent opioid formulations in the United States","volume":"129","author":"Webster","year":"2017","journal-title":"Postgraduate Medicine"},{"key":"10.1016\/j.jconrel.2026.114894_bb1075","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/11584260-000000000-00000","article-title":"Abuse-deterrent and tamper-resistant opioid formulations","volume":"24","author":"Schneider","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jconrel.2026.114894_bb1080","series-title":"Abuse-Deterrent Opioids \u2014 Evaluation and Labeling: Guidance for Industry","author":"US FDA","year":"2015"},{"key":"10.1016\/j.jconrel.2026.114894_bb1085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jconrel.2026.114894_bb1090","series-title":"Abuse-Deterrent Opioid Analgesics","author":"US FDA","year":"2021"},{"key":"10.1016\/j.jconrel.2026.114894_bb1095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc1204141","article-title":"Effect of abuse-deterrent formulation of OxyContin","volume":"367","author":"Cicero","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jconrel.2026.114894_bb1100","series-title":"U.S.P.a.T. Office (Ed.)","article-title":"Tamper resistant transdermal dosage form","author":"Howard","year":"2004"},{"key":"10.1016\/j.jconrel.2026.114894_bb1105","series-title":"U.S.P.a.T. Office (Ed.)","article-title":"Abuse-resistant transdermal dosage form","author":"Hart","year":"2010"},{"key":"10.1016\/j.jconrel.2026.114894_bb1110","series-title":"U.S.P.a.T. Office (Ed.)","article-title":"Transdermal dosage form","author":"Tang","year":"2015"},{"key":"10.1016\/j.jconrel.2026.114894_bb1115","series-title":"E.P. Office (Ed.)","article-title":"Abuse deterrent opiod\/opiod-antagonist transdermal patch","author":"Stinchcomb","year":"2015"},{"key":"10.1016\/j.jconrel.2026.114894_bb1120","series-title":"U.S.P.a.T. Office (Ed.)","article-title":"Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs","author":"Stinchcomb","year":"2007"},{"key":"10.1016\/j.jconrel.2026.114894_bb1125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2015.04.061","article-title":"Development and evaluation of a tampering resistant transdermal fentanyl patch","volume":"488","author":"Cai","year":"2015","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb1130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2017.12.031","article-title":"Generic patches containing fentanyl: In vitro equivalence and abuse deterrent evaluation according to EMA and FDA guidelines","volume":"537","author":"Padula","year":"2018","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114894_bb1135","series-title":"Alvogen Issues Voluntary Nationwide Recall for One Lot of Fentanyl Transdermal System 25 mcg\/h Due to a Defective Delivery System","author":"US FDA","year":"2025"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926002968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926002968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:11:22Z","timestamp":1793945482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926002968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":227,"alternative-id":["S0168365926002968"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114894","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transdermal delivery and formulation design of opioids: Where are we now and where are we heading?","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114894"}}